Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sternberg

Showing results (531-540 of 564) with videos related to

Pageof 57
Sort By:
JCO Precision Oncology|September 14, 2020
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort AnalysisAnuradha Jayaram, Anna Wingate, Daniel Wetterskog, et al.
The Lancet. Oncology|January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyCharles J Ryan, Matthew R Smith, Karim Fizazi, et al.
The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
Clinical Genitourinary Cancer|May 14, 2018
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access ProgramGiuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, et al.
Science (New York, N.Y.)|May 26, 2022
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targetsFanying Tang, Duo Xu, Shangqian Wang, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2025
Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancerMarjorie L Roskes, Alexander Martinez-Fundichely, Sandra Cohen, et al.
The New England Journal of Medicine|May 27, 2011
Abiraterone and increased survival in metastatic prostate cancerJohann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark TrialsJoaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
The Oncologist|July 21, 2021
Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma TestingWael Al Zoughbi, Jesse Fox, Shaham Beg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2021
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update ConsortiumSilke Gillessen, Nicolas Sauvé, Laurence Collette, et al.
Pageof 57

Showing results (531-540 of 564) with videos related to

Sort By:
Pageof 57
JCO Precision Oncology|September 14, 2020
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort AnalysisAnuradha Jayaram, Anna Wingate, Daniel Wetterskog, et al.
The Lancet. Oncology|January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyCharles J Ryan, Matthew R Smith, Karim Fizazi, et al.
The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
Clinical Genitourinary Cancer|May 14, 2018
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access ProgramGiuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, et al.
Science (New York, N.Y.)|May 26, 2022
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targetsFanying Tang, Duo Xu, Shangqian Wang, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2025
Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancerMarjorie L Roskes, Alexander Martinez-Fundichely, Sandra Cohen, et al.
The New England Journal of Medicine|May 27, 2011
Abiraterone and increased survival in metastatic prostate cancerJohann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark TrialsJoaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
The Oncologist|July 21, 2021
Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma TestingWael Al Zoughbi, Jesse Fox, Shaham Beg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2021
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update ConsortiumSilke Gillessen, Nicolas Sauvé, Laurence Collette, et al.
Pageof 57